A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers Meeting Abstract


Authors: Hong, D. S.; Younes, A.; Fayad, L.; Fowler, N. H.; Hagemeister, F. B.; Mistry, R.; Nemunaitis, J. J.; Borad, M. J.; Bryce, A. H.; Yamashita, M.; Hughes, S. G.; Kwoh, T. J.; MacLeod, A. R.; Norris, D.; Baldwin, R.; Hung, G. N.; Monia, B. P.; Kurzrock, R.
Abstract Title: A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers
Meeting Title: 49th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 31
Issue: 15 Suppl.
Meeting Dates: 2013 May 31-Jun 4
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2013-05-20
Language: English
ACCESSION: WOS:000335419602619
PROVIDER: wos
Notes: Meeting Abstract: 8523 -- Source: Wos